The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Molecular Pathways Mediating Quiescence And Resistance In Leukaemia Stem Cells In Acute Myeloid Leukaemia.
Funder
National Health and Medical Research Council
Funding Amount
$100,381.00
Summary
Acute myeloid leukaemia (AML) is a devastating cancer of the blood and bone marrow which is rapidly fatal unless effectively treated with chemotherapy. AML is caused by genetic events that alter normal blood stem cells to give them a growth and survival advantage and also may confer resistance to chemotherapy in some cases. We will evaluate and target the mechanism of this resistance in laboratory models. This information can then be used to design new treatments to improve outcomes in AML.
MicroRNA Expression And Genome-Wide Epigenetic Analysis Of Paediatric Acute Lymphoblastic Leukaemia (ALL)
Funder
National Health and Medical Research Council
Funding Amount
$71,765.00
Summary
Acute Lymphoblastic Leukaemia (ALL) is one form of childhood leukaemia, the causes for which are unknown. Evidence suggests genome changes are associated with ALL, specifically epigenetic changes such as DNA methylation and microRNA dysregulation. We aim to investigate these changes associated with childhood ALL. We believe this will refine the current diagnostic measures, more accurately predict patients� treatment response, and detect the minimal residual disease during and after treatment.
Mechanisms For The Development Of Leukaemia Via Antibody Hypermutation
Funder
National Health and Medical Research Council
Funding Amount
$82,421.00
Summary
During responses to infection, the antibody genes in responding B cells mutate at a high rate, resulting in B cells producing better antibodies. Although essential for long-lived immunity, antibody mutation involves the introduction of DNA breaks which can occasionally cause leukemia or lymphoma. We understand only poorly how DNA repair systems normally make sure that antibody mutation is benign and does not cause cancer.